INCY Stock - Incyte Corporation
Unlock GoAI Insights for INCY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.24B | $3.70B | $3.39B | $2.99B | $2.67B |
| Gross Profit | $3.86B | $3.38B | $3.14B | $2.80B | $2.51B |
| Gross Margin | 91.1% | 91.5% | 92.5% | 93.7% | 93.9% |
| Operating Income | $80.14M | $651.77M | $599.56M | $637.54M | $-240,291,000 |
| Net Income | $32.62M | $597.60M | $340.66M | $948.58M | $-295,697,000 |
| Net Margin | 0.8% | 16.2% | 10.0% | 31.8% | -11.1% |
| EPS | $0.16 | $2.67 | $1.53 | $4.30 | $-1.36 |
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 8th 2025 | Mizuho | Upgrade | Outperform | $121 |
| November 3rd 2025 | Guggenheim | Upgrade | Buy | $125 |
| October 8th 2025 | Oppenheimer | Downgrade | Perform | - |
| August 6th 2025 | Wells Fargo | Upgrade | Overweight | $89 |
| August 1st 2025 | Barclays | Initiation | Overweight | $90 |
| June 16th 2025 | Stifel | Upgrade | Buy | $107 |
| March 18th 2025 | Guggenheim | Downgrade | Neutral | - |
| March 18th 2025 | William Blair | Downgrade | Market Perform | - |
| December 17th 2024 | UBS | Initiation | Neutral | $77 |
| October 29th 2024 | BofA Securities | Upgrade | Buy | $90← $68 |
| October 1st 2024 | Wolfe Research | Initiation | Outperform | $84 |
| September 18th 2024 | Truist | Downgrade | Hold | $74← $83 |
| July 2nd 2024 | BMO Capital Markets | Downgrade | Underperform | $48← $52 |
| May 23rd 2024 | Deutsche Bank | Initiation | Hold | $55 |
| April 23rd 2024 | Cantor Fitzgerald | Initiation | Neutral | - |
Earnings History & Surprises
INCYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 9, 2026 | $1.96 | — | — | — |
Q4 2025 | Oct 28, 2025 | $1.66 | $2.26 | +36.1% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $1.39 | $1.57 | +12.9% | ✓ BEAT |
Q2 2025 | Apr 29, 2025 | $1.01 | $1.16 | +14.9% | ✓ BEAT |
Q1 2025 | Feb 10, 2025 | $1.57 | $1.43 | -8.9% | ✗ MISS |
Q4 2024 | Oct 29, 2024 | $1.12 | $1.07 | -4.5% | ✗ MISS |
Q3 2024 | Jul 30, 2024 | $0.78 | $-1.82 | -333.3% | ✗ MISS |
Q2 2024 | Apr 30, 2024 | $0.84 | $0.64 | -23.8% | ✗ MISS |
Q1 2024 | Feb 13, 2024 | $1.16 | $1.06 | -8.6% | ✗ MISS |
Q4 2023 | Oct 31, 2023 | $1.09 | $1.10 | +0.9% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $0.83 | $0.99 | +19.3% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $0.85 | $0.37 | -56.5% | ✗ MISS |
Q1 2023 | Feb 7, 2023 | $0.59 | $0.62 | +5.1% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $0.72 | $0.60 | -16.7% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $0.79 | $1.01 | +27.8% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $0.57 | $0.55 | -3.5% | ✗ MISS |
Q1 2022 | Feb 8, 2022 | $0.84 | $0.10 | -88.1% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $0.76 | $1.18 | +55.3% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $0.74 | $0.80 | +8.1% | ✓ BEAT |
Latest News
European Commission Approves Incyte's Minjuvi In Combination With Lenalidomide And Rituximab For Relapsed or Refractory Follicular Lymphoma
📈 PositiveIncyte's INCA033989 Shows 90% Hematologic Response In High-Dose ET Patients, Frequent Durable Molecular Responses, Favorable Safety Profile, And Receives FDA Breakthrough Therapy Designation In Updated Phase 1 Data Presented At ASH 2025
📈 PositiveMorgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $92
➖ NeutralWells Fargo Maintains Overweight on Incyte, Raises Price Target to $116
📈 PositiveMizuho Upgrades Incyte to Outperform, Raises Price Target to $121
📈 PositiveIncyte Announced Sunday, FDA Breakthrough Therapy Designation For Its Treatment For Essential Thrombocythemia With Type 1 CALR Mutation
📈 PositiveBarclays Maintains Overweight on Incyte, Raises Price Target to $115
📈 PositiveIncyte Reports Minjuvi Combination Therapy Achieves Significant Progression Free Survival Improvement In Relapsed Or Refractory Follicular Lymphoma With Positive CHMP Opinion
📈 PositiveIncyte Expands Its Moments of Clarity Program To Add Six New Stories To Spotlight Vitiligo And Mild-to-moderate Atopic Dermatitis
📈 PositivePiper Sandler Maintains Overweight on Incyte, Raises Price Target to $102
📈 PositiveIncyte inks option agreement with Prelude for JH2 inhibitor program
📈 PositivePrelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patients With Myeloproliferative Neoplasms
📈 PositiveGuggenheim Upgrades Incyte to Buy, Announces $125 Price Target
📈 PositiveRBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $84
➖ NeutralTruist Securities Reiterates Hold on Incyte, Raises Price Target to $93
➖ NeutralWells Fargo Maintains Overweight on Incyte, Raises Price Target to $97
📈 PositiveIncyte Raises FY25 Net Product Revenue Guidance To $4.23B - $4.32B; Lifts Guidance For Jakafi To $3.050B - $3.075B
📈 PositiveIncyte Q3 Adj. EPS $2.26 Beats $1.66 Estimate, Sales $1.366B Beat $1.255B Estimate
📈 PositiveIncyte Partners With Enable Injections to Develop Easier At-Home Treatments for Rare Blood Cancers
📈 PositiveReported Saturday, Incyte Reports Significant Patient-Reported Benefit In TRuE-AD4 With Improved POEM And DLQI Scores And Reduced Worst Daily Itch From Day 2
📈 PositiveFrequently Asked Questions about INCY
What is INCY's current stock price?
What is the analyst price target for INCY?
What sector is Incyte Corporation in?
What is INCY's market cap?
Does INCY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to INCY for comparison